Clinical Trial Update: A Study of Amivantamab and Olomorasib Combination Therapy in Participants With Metastatic Non-Small Cell Lung Cancer [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 trial investigating the combination of amivantamab and olomorasib in participants with metastatic non-small cell lung cancer is currently recruiting…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Olomorasib (olomorasib)
• RYBREVANT (amivantamab-vmjw)

Snippet

Sponsor: Janssen Research & Development, LLC | Conditions: Carcinoma, Non-Small-Cell Lung | Phase 1, Phase 2 | Status: RECRUITING